4.3 Article

ESPGHAN Revised Porto Criteria for the Diagnosis of Inflammatory Bowel Disease in Children and Adolescents

期刊

出版社

LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/MPG.0000000000000239

关键词

Crohn disease; diagnosis; inflammatory bowel disease-unclassified; inflammatory bowel disease; ulcerative colitis

资金

  1. MSD
  2. Abbott
  3. Ferring
  4. Falk
  5. Nestle
  6. Immundiagnostik
  7. Danone
  8. Janssen
  9. Shire
  10. Centocor
  11. Pfizer
  12. Biocodex
  13. Tillotts Pharma
  14. Dr Falk
  15. BioCare
  16. Falk-Foundation
  17. Norgine
  18. Pfrimmer
  19. Mead Johnson
  20. Novalac
  21. Abbvie
  22. Danone Reearch
  23. Ewopharma
  24. Nutricia
  25. Otsuka
  26. Fresenius Kabi
  27. Warner Chilcott
  28. MRC [G0800675] Funding Source: UKRI
  29. Crohn's and Colitis UK [M11-1] Funding Source: researchfish
  30. Medical Research Council [G0800675] Funding Source: researchfish
  31. Medical Research Foundation [C0482] Funding Source: researchfish

向作者/读者索取更多资源

Background:The diagnosis of pediatric-onset inflammatory bowel disease (PIBD) can be challenging in choosing the most informative diagnostic tests and correctly classifying PIBD into its different subtypes. Recent advances in our understanding of the natural history and phenotype of PIBD, increasing availability of serological and fecal biomarkers, and the emergence of novel endoscopic and imaging technologies taken together have made the previous Porto criteria for the diagnosis of PIBD obsolete.Methods:We aimed to revise the original Porto criteria using an evidence-based approach and consensus process to yield specific practice recommendations for the diagnosis of PIBD. These revised criteria are based on the Paris classification of PIBD and the original Porto criteria while incorporating novel data, such as for serum and fecal biomarkers. A consensus of at least 80% of participants was achieved for all recommendations and the summary algorithm.Results:The revised criteria depart from existing criteria by defining 2 categories of ulcerative colitis (UC, typical and atypical); atypical phenotypes of UC should be treated as UC. A novel approach based on multiple criteria for diagnosing IBD-unclassified (IBD-U) is proposed. Specifically, these revised criteria recommend upper gastrointestinal endoscopy and ileocolonscopy for all suspected patients with PIBD, with small bowel imaging (unless typical UC after endoscopy and histology) by magnetic resonance enterography or wireless capsule endoscopy.Conclusions:These revised Porto criteria for the diagnosis of PIBD have been developed to meet present challenges and developments in PIBD and provide up-to-date guidelines for the definition and diagnosis of the IBD spectrum.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.3
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据